A Debate—Resolved: Immunohistochemistry Should Be Regulated As An Assay

Join G2 Intelligence for this interactive discussion about whether clinical immunohistochemistry testing should be a stain or an assay, with our experts offering arguments for and against the proposed changes

Thursday, April 25

11:00 AM EDT

Is clinical immunohistochemistry (IHC) testing a stain or an assay? This seemingly pedantic question has become an important topic in anatomic pathology with significant industry implications. In August 2023, Dr. BJ Magnani and Dr. Clive Taylor advocated for a substantial overhaul of IHC testing regulation in an Archives of Pathology & Laboratory Medicine editorial. They argued that the current lower level of quality assurance, suitable when IHC was considered a mere “stain,” is outdated. IHC has evolved into a critical assay format for cellular protein expression, influencing crucial therapeutic decisions. To reduce error rates, IHC quality assurance protocols must adapt to this paradigm shift. The National Society of Histotechnology (NSH) promptly and publicly endorsed the editorial’s proposal. Additional outpourings of support emerged, all within half a year of the online publication. Dr. Steve Bogen and Dr. Emina Torlakovic will delve into this debate in this webinar, presenting arguments for and against the proposed changes.


Steve Bogen, MD, PhD
Boston Cell Standards Inc.

Dr. Emina Emilia Torlakovic
Division Head of Hematopathology, Saskatchewan Health Authority;
Professor, University of Saskatchewan

The information you provide will be shared with the sponsors of this content. G2 Intelligence or its sponsors may contact you to offer you content or products based on your interest in this topic. You may unsubscribe from these communications at any time. For information on how to unsubscribe, our privacy practices, and commitment to protecting your privacy, check out our Privacy Policy.